# Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

> **NCT01569113** · PHASE4 · COMPLETED · sponsor: **HRA Pharma** · enrollment: 76 (actual)

## Conditions studied

- Emergency Contraception

## Interventions

- **DRUG:** Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)
- **DRUG:** placebo + ethinylestradiol/levonorgestrel

## Key facts

- **NCT ID:** NCT01569113
- **Lead sponsor:** HRA Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2013-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569113, "Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01569113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*